CRH — CRH plc

As of 2026-08-27, the tape is cautious: price down 1.5% on the day, roughly 27% off the high, below the 20/50/200-day SMAs, and RSI at 43.54. That price action is happening even though Q2 2026 revenue of $10.78B and EPS of $2.21 beat consensus and management reaffirmed FY26 guidance of $3.9-4.1B net income; sell-side ratings remain overwhelmingly Buy. The net sentiment is mixed—good fundamentals, poor technicals, and rate-driven cyclical rotation.

Using the clean quarterly rows (the 2025-12-31 entry looks like a full-year/annual row and should be ignored for sequential comparisons), CRH is inflecting upward. Q2 2026 revenue rose 23.7% YoY to $10.78B from $8.71B, operating income rose roughly 27% to $2.08B, and net income rose roughly 33% to $1.49B. H1 2026 revenue was $18.15B versus $15.47B in H1 2025, up 17.3%; H1 operating margin expanded from about 10.6% to 11.2% and gross margin from about 34.1% to 34.9%. Q1 losses are seasonal, not deterioration. This is broad-based acceleration, not a one-quarter blip.

As of 2026-08-27, headline trailing P/E of 14.91 and P/S of 1.10 look cheap versus 5-year averages of 16.21 and 1.65, but FMP's TTM inputs are distorted by a full-year row in the quarterly file. On forward numbers, price against consensus FY26 EPS of $5.91 is about 16.2x, and price against guidance-midpoint EPS of roughly $5.99 is about 16.0x—basically in line with CRH's own 5-year average. With a 2.02 PEG ratio, the stock is fairly valued on a forward basis, not statistically cheap.

The market has de-rated CRH from roughly $131 to $95 even though earnings estimates and guidance have held up, so the stock now trades at about its historical average forward multiple rather than pricing in the infrastructure boom. If IIJA spending and private non-residential demand keep margins expanding, current estimates are conservative and the stock can re-rate toward the $120s; if the cycle rolls over, 16x forward earnings on a falling EPS number provides less cushion than the headline trailing P/E suggests. The playbook is to watch FY26 EPS revisions: holding above $5.90 supports the current price, while cuts would open a path to sub-$85.

As of 2026-08-27, RSI was 43.54—not oversold—while price was 1.57% below the 20-day SMA, 6.2% below the 50-day, and 14.7% below the 200-day. The stock is in a persistent downtrend, sitting near its 52-week low of $92.52, and there is no confirmed reversal. The timing implication: wait for a reclaim of the 20-day or a volatility washout with RSI below roughly 30 before adding; the current technicals do not support a low-risk entry.

• Approximately 50% of IIJA federal infrastructure funds remain undeployed, providing a multi-year floor for highway and transportation spending.
• Interest rate volatility and higher-for-longer financing costs are weighing on construction activity and causing rotation out of basic-materials cyclicals.
• Private non-residential demand—manufacturing plants, data centers, and clean energy—is offsetting softness in residential and some commercial segments.
• Cement and aggregates pricing power is helping margins, but input cost inflation and freight/energy costs remain a swing factor.
• Close regulatory/antitrust scrutiny of the $8.5B Arcosa acquisition and the resulting step-up in leverage.

• Regulatory clearance and early-2027 closing of the Arcosa acquisition, plus realization of the $175M annual cost synergy target.
• Q3 2026 earnings in late October/early November 2026 for cash conversion, margin exit rate, and any FY26 guidance update.
• Further capital recycling via additional bolt-on M&A or share buyback tranches.
• H2 peak construction season execution on heavy highway and water infrastructure projects.

• Interest rates resume climbing, hitting construction volumes and pressuring the multiple further.
• Arcosa integration risk and higher debt load; debt/equity is already 0.82 before an $8.5B all-cash deal.
• Cyclical downturn in North American construction—volume and pricing could roll over faster than consensus expects.
• Data/comparability issues in the FMP series (an annual row masquerading as a quarter) reduce confidence in exact trailing metrics.
• Geographic concentration in North American materials leaves the model sensitive to a regional slowdown.

CRH is a well-managed, high-quality materials business with accelerating H1 2026 results and strong secular infrastructure tailwinds, but the stock is not a distressed bargain: at roughly 16x forward earnings it is fairly valued, and the technical setup is still negative. For a long-term investor, $95 is a reasonable accumulation zone, but I would not chase absent either a better technical entry or evidence that estimates are moving up.

Applied a justified forward P/E of 17.0x—a slight premium to CRH's 5-year average of 16.21x, reflecting infrastructure tailwinds, pricing power, and buybacks—to FY2026 EPS of roughly $5.99 (midpoint of $3.9-4.1B net income guidance on about 668M shares), giving $101.83. This is intentionally below the sell-side average target because that target implies a roughly 23x forward multiple.